Celcuity (CELC) Stock Forecast & Price Target

Celcuity is supported by gedatolisib’s differentiated pan-PI3K/mTOR profile, which has already shown compelling efficacy and tolerability in Phase 3 VIKTORIA-1, including a primary-endpoint win in the PIK3CA mutant cohort by doubling the likelihood of progression-free survival versus alpelisib plus fulvestrant. Its outlook is further strengthened by commercial readiness for REVTORPYK, with pricing near $30,000 per cycle, a 20% gross-to-net assumption, 1,000+ KOLs/community oncologists engaged, 250+ key accounts engaged, and $754 million in cash providing runway into >2029. With VIKTORIA-2 and CELC-G-201 ongoing, plus a planned sNDA submission in 3Q26 and expanding label potential across HR+/HER2- disease, the company has multiple near- and longer-term catalysts that can support meaningful value creation.

Celcuity is a clinical-stage biotechnology company whose outlook is pressured by high execution risk, because gedatolisib must still prove it can deliver durable efficacy and safety across multiple ongoing and completed trials, including VIKTORIA-1, VIKTORIA-2, and CELC-G-201. Despite the mechanistic appeal of inhibiting all class I PI3K isoforms and mTORC1/2, the company faces intense competition in crowded HR+/HER2- breast cancer and mCRPC markets, where commercial success, physician adoption, and reimbursement are far from assured. The investment case is further weakened by financial strain typical of development-stage biotechs, including the likelihood of additional equity financing that could dilute shareholders if regulatory delays or trial setbacks prevent approval.